“We needed to disrupt the way we do clinical trials. The idea of “disruptive innovation” in clinical trials was making a trial more accessible and cheaper for the end user, the patient,” said Valerie Bowling, Executive Director, DPHARM.
NEW YORK (PRWEB)
June 24, 2020
The Conference Forum is pleased to announce the launch of the DPHARM newsletter. This is the first publication solely dedicated to highlighting the voices committed to bold ideas that shake up the way we conduct clinical trials to bring research to where the patients are and reduce the failure rates. The DPHARM newsletter builds on the success of the company’s DPHARM conference.
Through a wide variety of perspectives including pharma R&D, outside pharma, biopharma, academic, outside industry and patient advocacy perspectives, the newsletter challenges and reports on innovation to shake up the way we do clinical trials to reduce the burden to patients and investigators.
“We needed to disrupt the way we do clinical trials. The idea of “disruptive innovation” in clinical trials was making a trial more accessible and cheaper for the end user, the patient,” said Valerie Bowling, Executive Director, DPHARM.
The following interviews are featured in the inaugural issue:
Jeri Burtchell, patient activist, writer, Director of Patient Initiatives, HealthiVibe, gives the patient perspective on participating in a clinical trial, as well as some tips for pharma;
Esther Dyson, investor and the executive founder of Wellville, discusses investing in innovation for long-term wellness;
Craig Lipset, founding chair and adviser of DPHARM, traces where we’ve been in clinical innovation, and where we might be headed;
Tammy Guld, Global Team Lead, Janssen Clinical Innovation, shares how collaboration at Janssen is proving to be the key breakthrough in clinical trials;
Deirdre BeVard, SVP, R&D Strategic Operations, CSL Behring, gives her perspective as a clinical operations veteran on moving the innovation needle to advance drug development;
Benjamine Liu, DPhil, co-founder and CEO, TrialSpark, discusses Project Covalence, the turnkey trial platform that enables the rapid launch of clinical trials for COVID-19.
The issue ends with a recap from the archive: Mark Johnston, then Director of Global Business Development, Amazon Web Services, who presented on how to innovate like Amazon in clinical trials at DPHARM 2018.
The Conference Forum will also launch the DPHARM: Disruptive Innovations event later this week with an exciting line-up of innovative speakers from Regeneron to the FDA to the author of Freakonomics. With the conferences, podcasts and quarterly newsletters, the company provides comprehensive coverage on insights and ongoing support for the clinical research community.
About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.
The Conference Forum presents strategic level conferences, both public and private, as well as developing focus groups and advisory boards for professionals in the life science and healthcare industries. They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters, reports and produces podcasts.
Learn more about The Conference Forum at theconferenceforum.org
Share article on social media or email: